Table 2.

Randomized, controlled trials on venous and arterial thromboembolic risk associated with ramucirumab

Randomized controlled trials	Regimen (N)	VTE (any grade)	VTE (grade ≥ 3)
VTE
REGARD (2nd line GADC, EGJ-ADC), Fuchs et al.15	RM (236) Placebo (115)	4%	1%
		7%	4%
RAIBOW (2nd line GADC, EGJ-ADC), Wilke et al.18	RM + paclitaxel (327) placebo + paclitaxel (329)	4%	2.4%
		5.5%	3.3%
REVEL (2nd line NSCLC), Garon et al.16	RM + Docetaxel (627) Placebo + Docetaxel (618)	3%	2%
		6%	3%
ROSE/TRIO-12 (1st line mBC), Mackey et al.17	RM + Docetaxel (752) Placebo + Docetaxel (382)	2.4%	1.3%*
		4.2%	2.1%*
Randomized controlled trials	Regimen (N)	ATE (any grade)	ATE (grade ≥ 3)
ATE
REGARD (2nd line GADC, EGJ-ADC), Fuchs et al.15	RM (236) Placebo (115)	2%	1%
		0%	0%
RAIBOW (2nd line GADC, EGJ-ADC), Wilke et al.18	RM + paclitaxel (327) placebo + paclitaxel (329)	1.5%	0.9%
		1.8%	0.9%
REVEL (2nd line NSCLC), Garon et al.16	RM + Docetaxel (627) Placebo + Docetaxel (618)	2%	1%
		2%	1%
ROSE/TRIO-12 (1st line mBC), Mackey et al.17	RM + Docetaxel (752) Placebo + Docetaxel (382)	1.1%	0.7%
		1.3%	0.3%

ATE, arterial thromboembolism; EGJ-ADC, oesophago-gastric junction adenocarcinomas; GADC, gastric adenocarcinomas; mBC, metastatic breast cancer; N, number of patients; NSCLC, non-small-cell lung cancer; RM, ramucirumab; VTE, venous thromboembolism.

^* P < 0.05.